Printer Friendly

Body Mass Index, Haemoglobin, and Total Lymphocyte Count as a Surrogate for CD4 Count in Resource Limited Settings.

1. Introduction

HIV/AIDS infection continues to pose threats to patients due its devastating effect on the human CD4 cells [1]. The HIV/AIDS virus's ability to weaken the immune system results in a number of disorders including wasting syndrome [2], hematological derangements such as anemia [3], lymphopenia [4], and thrombocytopenia [5] which are the most common cause of HIV related mortality and morbidity [6].

In recent times one of the greatest challenges in the management and care of HIV in poor resource settings has been the evaluation of CD4 count measurement; a parameter which is seen as a traditional biomarker for predicting the progression and monitoring treatment response to highly active antiretroviral therapy (HAART) [7]. The frequency with which costly CD4 counts are administered to monitor treatment efficacy as well as therapeutic regimens continues to be a burden to many underdeveloped countries; therefore the need for an alternate cost effective, easily performed, and readily available surrogate markers that can assist in predicting the disease progression and patient's response to HAART is needed in these settings.

Among HIV infected individuals, studies have indicated a positive association between higher BMI [8], TLC (1200 cell/ ul) [9], and Hb [10] (less than 10 g/dL) with CD4 counts (<350 and <200 cells/[mm.sup.3]). A study reports that, being obese or overweight was independently associated with higher CD4 counts, compared to their nonobese (18.5-24.9 kg/[m.sup.2]) controls [11]. Decrease in Hb levels correlates positively with CD4 cell counts [12]. Anemia, an independent predictor of HIV/AIDS progression, has been found to improve with antiretroviral treatment [10]. Several studies have also indicated adequate sensitivity and specificity to consider TLC as a surrogate measure for CD4 count [13]. Despite these successes, few studies have evaluated the predictability of BMI, Hb, and TLC as surrogate markers to CD4 counts in Ghana.

In view of the lack of evidence on the possibility of an economically viable, easy, and readily available biomarker to substitute the traditional role of CD4 counts in HIV disease progression, this study investigated the potential use of BMI, Hb, and TLC as surrogate biomarkers for monitoring HIV disease progression in Ghana.

2. Methods

2.1. Participants and Study Design. This cross-sectional study was undertaken at the ART clinic of the Bomso hospital in the Ashanti region of Ghana from August 2015 to March 2016. We recruited a total of 384 individuals who were 18 years or older and were confirmed HIV seropositive patients at the facility. Our subjects included 208 HIV HAART and 176 HIV HAART naive patients. Participants who were pregnant and had HIV confections including other opportunistic infections were excluded from the study.

We categorized participants into three groups based on their CD4 lymphocyte counts in accordance with the Center for Disease Control classification. The groups were CD4 counts less than 200 [mm.sup.-3], between 200 and 499 [mm.sup.-3], whereas the third group consisted of patients with CD4 count above 500 [mm.sup.-3]. All study protocol was reviewed and approved by the Committee on Human Research and Publication of the Kwame Nkrumah University of Science and Technology (KNUST) and informed consent was also sought from all the participants.

2.2. Measurement of BMI. We measured the weight of participants at baseline during their periodic ART clinic visits. The height of subjects was however measured during their first visit only. Height was measured with a stadiometer and rounded to the nearest 0.1 cm. The Tanita HD-351 Scale was used for weight measurement and rounded to the nearest 0.05 kg. BMI was calculated using the formula (body weight in kilograms)/[(height in meters).sup.2].

2.3. Measurement of CD4 Counts, Haemoglobin, and T Lymphocyte. CD4 counts, Hb, and TLC were measured by drawing 3 mL of venous blood from each participant under sterile conditions after applying a tourniquet for less than a minute into anticoagulated sequestrene bottles (EDTA). A complete blood count, including Hb, white blood counts, and lymphocytes with automated differential, was measured. The TLC was calculated by multiplying the white blood count by the automated percent lymphocytes. The full blood count was determined using an autoanalyzer (Cell DNY1800 from Abbott Diagnostics Division, USA). CD4 analysis was done with the use of the Becton Dickenson and company haematological analyzer called the BD FACSCount from California in USA. The BD FACSCount system used flow cytometry for the quantification of the CD4 T lymphocytes. The laboratory analysis followed a standard flow cytometry performed in laboratories certified by the National Institute of Allergies and Infectious Diseases (NIAID) Flow Cytometry Quality Assessment Program.

2.4. Data Analysis. All statistical analyses were performed with SPSS version 22. Data were presented as median interquartile range (IQR) for nonparametric variables whiles grouped variables were expressed as proportions. We performed a Mann-Whitney U test to compare the differences between HAART naive and HAART patients for Hb, BMI, and TLC. Kruskal-Wallis test was performed to determine the extent to which Hb, BMI, and TLC influence HIV disease progression. We further performed a linear regression test to determine the associations that exist between CD4 count and Hb, BMI, and TLC. Suitable cut-off point was determined for Hb, BMI, and TLC using Youden's index. The performance of Hb, BMI, and TLC was assessed using the area under the curve from the receiver operator characteristics. Positive and negative predictive values were also calculated. All statistical significance were accepted at p < 0.05.

3. Results

3.1. Baseline Characteristics of Study Participants. Table 1 shows the demographic and clinical characteristics of the study participants. Out of the three hundred and eighty-four (384) participants, the majority (69.8%) were females in both the HAART and the HAART untreated patients. The median age of the HAART group (41 yrs) was not statistically different from the HAART untreated group (40 yrs). The median CD4 counts of the HAART group (458 [mm.sup.-3]) were significantly higher than the HAART untreated group (229 [mm.sup.-3]); p < 0.0001. The median BMI, Hb, and TLC of HAART patients were significantly different from the HAART untreated patients as detailed in Table 1.

3.2. Hb, BMI, and Total Lymphocyte Count in HIV Disease Progression. Table 2 describes the trend of Hb, BMI, and T lymphocyte in the disease progression. Hb, BMI, and TLC were found to decrease significantly (p [less than or equal to] 0.0001) as the disease progresses with lowest median values among patients with CD4 less than 200 [mm.sup.-3] for Hb (11.4 g/dL), BMI (19.2 kg/[m.sup.2]), and TLC (1989 [mm.sup.-3]).

3.3. Predictive Performance of Haemoglobin, BMI, and Total Lymphocyte Count. Table 3 describes the predictive performance of Hb, BMI, and TLC in predicting HIV disease progression among the studied participants: HAART and the HAART untreated. At a cut-off point of 12.15 g/L, Hb had sensitivity and specificity of 73.9% and 56.8%, respectively, while BMI had 69.6% and 80.1% for sensitivity and specificity, respectively. The sensitivity and specificity were also 100% among the studied participants at a cut-off point of 1200 [mm.sup.-3] for TLC. The area under the curve for Hb, BMI, and TLC was 0.688, 0.780, and 1.000, respectively, for the total study participants. The area under the curve of all the biomarkers was very high in both HAART and HAART untreated patients. In the HAART patients, the area under the curve was 0.679, 0.789, and 1.00 for Hb, BMI, and TLC, respectively, whereas, in the HAART untreated patients, this was 0.658, 0.817, and 1.00 for Hb, BMI, and TLC, respectively.

TLC had the highest positive (91.3%) and negative predictive (87.6%) values followed by BMI (PPV 71.7%, NPV 51.4%). Hb had the lowest positive (67.4%) and negative predictive (21.2%) values.

Figures 1, 2, and 3 are scatter plots depicting the correlations of CD4 count with Hb, BMI, and TLC. There was a significant positive correlation between CD4 count and haemoglobin (rho 0.262, p = 0.0001), BMI (rho 0.301, p = 0.0001), and TLC (rho 0.834, p = 0.0001).

4. Discussion

This study was conducted to assess whether Hb, BMI, and TLC can be used as a surrogate for CD4 count. The use of CD4 counts to assess disease progression and to guide treatment among HIV positive persons is well established. The cost implication of CD4 testing however has sprouted the need to find a less expensive surrogate maker in limited resource settings. Previous evidence has shown the possibility of using TLC in this regard, although there has been lack of consensus on the cut-off for sensitivity or specificity. There has also been the call to assess other surrogate biomarkers that could be used in place of CD4 counts. This study sought to access the suitability of Hb, BMI, and TLC as surrogates for CD4 counts, using Youden's J index to establish the cuff-off where sensitivity and specificity are the highest.

This study was found TLC to be a good predictor of CD4 counts. At the cut-off of 1200 cells/[mm.sup.3], a sensitivity and specificity of 100% were observed for patients who were not on HAART treatment. The overall diagnostic performance using the AUC was equally very high (AUC = 1) in both HAART treated and HAART untreated groups thus indicating the use of TLC as a potential surrogate marker in remote and deprived areas of Ghana where scarcity of laboratory technologies is a good choice. Total lymphocyte count at a cut-off of 1200 cells/[mm.sup.3] is a good substitute for CD4 < 200 cell/[mm.sup.3] in remote and deprived areas of Ghana: thus, all individuals who need medication would be given the needed medication if a total lymphocyte count of 1200 cells/[mm.sup.3] was used, as recommended by the WHO. Also, patients in the advanced stage of the disease could be identified and given the needed attention and treatment if a cut-off of 1200 cells/[mm.sup.3] is used as a surrogate for CD4 count in our settings. This corroborates previous evidence that also found a high sensitivity and specificity for the same cut-off of TLC [9,14]. However conflicting results have been reported [15,16].

Bivariate associations showed a high positive correlation between TLC and CD4 counts and the mean level of TLC increased with increased levels of CD4 for both HAART treated and HAART untreated patients. This is also consistent with the study by Wang et al. [14], among HIV patients from four countries that observed a high positive correlation between TLC and CD4 counts before and after initiating HAART. Similar relationship was observed in other studies from limited resource settings [9, 13]. However, previous study by Mbanya et al. [17] reported a weak association between CD4 count and TLC and hence the limited value of TLC in predicting CD4 counts making it unsuitable to be substituted for CD4 counts. These differences in findings could be as a result of different ethnic, racial, epidemiological, and socioeconomic factors [18] among study participants.

This study further showed that BMI and Hb could also provide some useful prognostic information about HIV disease progression. A sensitivity, specificity, and AUC of 73.9%, 56.8%, and 0.688 for Hb and 69.9%, 80.1%, and 0.780 for BMI, respectively, were observed in predicting CD4 counts < 200 [mm.sup.-3]. These levels of AUC based on Youden's J index show a strong predictive ability of Hb and BMI at cut-offs of 12.15 kg/m and 20.65 g/dL, respectively. However, when haemoglobin and BMI are used as a substitute for CD4 at these cut-offs some of the patients who require medication will not be given the needed medication due to relatively low sensitivity and specificity. Further, patients in the advanced stage of the disease cannot be clearly identified and given the needed attention and treatment should these cut-off points be used a surrogate for CD4 count in our settings. There was also a significantly positive correlation between these biomarkers and CD4 counts in the studied population and a trend analysis revealed that an increase in Hb, BMI, and TLC is associated with an increase in the level of CD4 counts. Previous studies [19, 20] have reported higher BMI to be associated with an increased CD4 counts, improved immune reconstitution, and improved survival resulting in a slower disease progression. The trend relationship between Hb and CD4 counts has also been confirmed in previous studies. Earlier reports have also demonstrated that low levels of haemoglobin may be associated with AIDS and death in people with HIV [21, 22] indicating the prognostic value of haemoglobin measurement in the disease progression as evidence in this study. The significant positive correlation observed between haemoglobin levels and CD4 count in the studied participants coupled with the decrease in haemoglobin levels as the disease progress is indicative that haemoglobin measurement may independently provide prognostic information provided by CD4 counts in economically disadvantaged settings.

5. Conclusion

The study has shown that TLC, Hb, and BMI may provide some useful prognostic information independent of what is provided by the CD4 count. The regular measurement of these parameters in resource limited settings may therefore be useful to clinicians in monitoring patient's response to antiretroviral therapy and predicting the stage of the disease. This could possibly assist clinicians in identifying patients who are at higher risks of disease progression thereby reducing mortality caused by the HIV infection.
Abbreviations

BMI:     Body mass index
HIV:     Human immunodeficiency virus
HAART:   Highly active antiretroviral therapy
TLC:     Total lymphocyte count.


https://doi.org/10.1155/2017/7907352

Ethical Approval

Ethical approval was sought from the committee on human research and publication of the School of Medical Science, Kwame Nkrumah University of Science and Technology (KNUST). Participation was voluntary and verbal informed consent was obtained from each participant according to Helsinki Declaration. Respondents were assured that the information gathered was to be used strictly for research and academic purpose only. In addition, respondents were given the freedom to opt out any time they thought they could not continue with the study.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors' Contributions

Louis Boafo Kwantwi contributed to the research design, data analysis and interpretation of results, and first draft of the manuscript. Dan Yedu Quansah contributed to the conception of the research idea, interpretation of results, and first draft of the manuscript. Bismark Kwame Tunu contributed to data collection, design, and interpretation of results. Daniel Boateng contributed to data analysis and interpretation of results and critically reviewed the manuscript. Louis Boafo Kwantwi supervised all the work and had primary responsibility for the final content. All authors read and approved the manuscript for submission.

Acknowledgments

Gratitude goes to all patients who participated in the study.

References

[1] UNICEF and World Health Organization, "Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011," Tech. Rep., World Health Organization, Geneva, Switzerland, 2011.

[2] B. Denue, P. Ikunaiye, and Denue C., "Body mass index changes during highly active antiretroviral therapy in Nigeria/Modifications de l'indice de masse corporelle pendant le traitement antiretroviral hautement actif au Nigeria," Eastern Mediterranean Health Journal, vol. 19, no. 3, article S89, 2013.

[3] G. C. De Santis, D. M. Brunetta, F. C. Vilar et al., "Hematological abnormalities in HIV-infected patients," International Journal of Infectious Diseases, vol. 15, no. 12, pp. e808-e811, 2011.

[4] G. C. Davenport, C. Ouma, J. B. Hittner et al., "Hematological predictors of increased severe anemia in Kenyan children coinfected with Plasmodium falciparum and HIV-1," American Journal of Hematology, vol. 85, no. 4, pp. 227-233, 2010.

[5] A. Rios, "HIV-related hematological malignancies: a concise review," Clinical Lymphoma, Myeloma and Leukemia, vol. 14, pp. S96-S103, 2014.

[6] F. Bonnet, C. Lewden, T. May et al., "Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy," Cancer, vol. 101, no. 2, pp. 317-324, 2004.

[7] P. Balakrishnan, S. Solomon, N. Kumarasamy, and K. H. Mayer, "Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries," Indian Journal of Medical Research, vol. 121, no. 4, pp. 345-355, 2005.

[8] A. Sharma, S. A. Bynum, M. F. Schneider et al., "Changes in body mass index following HAART initiation among HIV-infected women in the women's interagency HIV study," Journal of AIDS and Clinical Research, vol. 5, no. 7, pp. 2-8, 2014.

[9] C. Obirikorang, L. Quaye, and I. Acheampong, "Total lymphocyte count as a surrogate marker for CD4 count in resource-limited settings," BMC Infectious Diseases, no. 1, article 128, 2012.

[10] V. Kandi and A. B. Bhatti, "Advantages of Alternate Biomarkers in the Management of Human Immunodeficiency Virus with Highly Active Antiretroviral Therapy," in Science and Education Publishing, 2016.

[11] A. Sharma, D. R. Hoover, Q. Shi et al., "Relationship between body mass index and mortality in HIV-infected HAART users in the women's interagency HIV study," PLoS ONE, vol. 10, no. 12, Article ID e0143740, 2015.

[12] S. Shah, C. J. Smith, F. Lampe et al., "Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretrovial therapy era: relationships with gender," HIV Medicine, vol. 8, no. 1, pp. 38-45, 2007.

[13] D. Daka and E. Loha, "Relationship between Total Lymphocyte count (TLC) and CD4 count among peoples living with HIV, Southern Ethiopia: a retrospective evaluation," AIDS Research and Therapy, no. 1, article 26, 2008.

[14] Y. Wang, S. Liang, E. Yu et al., "Correlation analysis on total lymphocyte count and CD4 count in HIV-infected patients: a retrospective evaluation," Journal of Huazhong University of Science and Technology--Medical Science, vol. 31, no. 5, pp. 712-716, 2011.

[15] A. L. D. Angelo, C. D. Angelo, A. J. L. Torres et al., "Evaluating total lymphocyte counts as a substitute for CD4 counts in the follow up of AIDS patients," Brazilian Journal of Infectious Diseases, vol. 11, no. 5, pp. 466-470, 2007.

[16] N. O. Akinola, O. Olasode, I. A. Adediran et al., "The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting," Clinical Infectious Diseases, vol. 39, no. 4, pp. 579-581, 2004.

[17] D. Mbanya, F. Assah, N. Ndembi, and L. Kaptue, "Monitoring antiretroviral therapy in HIV/AIDS patients in resource-limited settings: CD4 counts or total lymphocyte counts?" International Journal of Infectious Diseases, vol. 11, no. 2, pp. 157-160, 2007.

[18] S. M. Alavi, F. Ahmadi, and M. Farhadi, "Correlation between total lymphocyte count, hemoglobin, hematocrit and CD4 count in HIV/AIDS patients," Acta Medica Iranica, vol. 47, no. 1, pp. 1-4, 2009.

[19] J. R. Koethe, C. A. Jenkins, B. E. Shepherd, S. E. Stinnette, and T. R. Sterling, "An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy," Clinical Infectious Diseases, vol. 53, no. 9, pp. 952-960, 2011.

[20] C. Y. Jones, J. W. Hogan, B. Snyder et al., "Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort," Clinical Infectious Diseases, vol. 37, supplement 2, pp. S69-S80, 2003.

[21] A. J. Saah, D. R. Hoover, Y. He, L. A. Kingsley, and J. P. Phair, "Factors influencing survival after AIDS: report from the multicenter AIDS cohort study (MACS)," Journal of Acquired Immune Deficiency Syndromes, vol. 7, no. 3, pp. 287-295, 1994.

[22] C. Obirikorang and F. A. Yeboah, "Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting," Journal of Biomedical Science, vol. 16, no. 1, article 102, 2009.

Louis Boafo Kwantwi, (1) Bismark Kwame Tunu, (1) Daniel Boateng, (2) and Dan Yedu Quansah (3)

(1) Department of Molecular Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

(2) School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

(3) Department of Biomedical and Forensic Sciences, University of Cape Coast, Cape Coast, Ghana

Correspondence should be addressed to Louis Boafo Kwantwi; kwantwiboafo@yahoo.com

Received 24 December 2016; Revised 8 March 2017; Accepted 29 March 2017; Published 18 April 2017

Academic Editor: Swasti Tiwari

Caption: Figure 1: Scatter plots depicting the correlations of CD4 count and haemoglobin (Hb).

Caption: Figure 2: Scatter plots depicting the correlations of CD4 count and body mass index (BMI).

Caption: Figure 3: Scatter plots depicting the correlations of CD4 count and total lymphocyte count (TLC).
Table 1: Demographic and clinical characteristics of the studied
participants.

Parameter                    Total subjects (384)

Age (yrs.)                        40 (34-50)
Sex (n, %)
  Male                            116 (30.2)
  Female                          268 (69.8)
CD4 ([mm.sup.-3])               346.5 (202-503.3)
Hb (g/dL)                        12.1 (10.2-15.1)
BMI (kg/[m.sup.2])               22.9 (19.7-29.9)
T lymphocyte ([mm.sup.-3])       2615 (1232-3336)

Parameter                     HAART group (208)     HAART naive (176)

Age (yrs.)                       41 (35-53)           40 (31.3-50)
Sex (n, %)
  Male                          62 (16.1)             54 (14.1)
  Female                       146 (38.0)            122 (31.8)
CD4 ([mm.sup.-3])            458.0 (307.5-633.8)   229.0 (136.3-338.8)
Hb (g/dL)                     13.4 (12.6-14.2)      10.6 (10.4-12.8)
BMI (kg/[m.sup.2])            26.3 (24.3-28.9)      23.5 (19.1-24.9)
T lymphocyte ([mm.sup.-3])    3225 (2547-3230)      1989 (1145-2605)

HAART highly active antiretroviral therapy.

Table 2: Haemoglobin, BMI, and total lymphocyte count in HIV disease
progression.

Parameter                           <200           CD4 count 200-499

Total

BMI (kg/[m.sup.2])            19.2 (17.9-21.9)      23.9 (21.1-27.3)
Hb(g/dL)                      11.4 (10.1-12.225)    12.2 (11.2-13.1)
T lymphocyte ([mm.sup.-3])    1114 (1087-1161)      2595(2307-2837)

HAART group

BMI (kg/[m.sup.2])            11.8 (11.35-12.15)   12.4 (11.55-13.25)
Hb (g/dL)                     21.7 (19.5-24.8)     25.6 (20.4-26.1)
T lymphocyte ([mm.sup.-3])    1122 (1072-1172)     2680 (2490-2990)

HAART naive group

BMI (kg/[m.sup.2])            10.0 (9.73-11.50)    11.70 (10.90-12.90)
Hb (g/dL)                     18.2 (19.2-22.9)     22.5 (20.1-24.6)
T lymphocyte ([mm.sup.-3])    1122 (1072-1172)     2680 (2490-2990)

Parameter                    [greater than or     p value
                               equal to] 500

Total

BMI (kg/[m.sup.2])             24 (22.1-28.6)     <0.0001
Hb(g/dL)                      12.6 (11.7-13.6)    <0.0001
T lymphocyte ([mm.sup.-3])    3534 (3476-3650)    <0.0001

HAART group

BMI (kg/[m.sup.2])            13.5 (11.65-15.55)   0.153
Hb (g/dL)                     27.1 (23.4-29.9)     0.005
T lymphocyte ([mm.sup.-3])    3550 (3477-3650)    <0.0001

HAART naive group

BMI (kg/[m.sup.2])            12.0 (10.75-13.15)    0.027
Hb (g/dL)                     23.9 (22.6-27.4)     <0.0001
T lymphocyte ([mm.sup.-3])    3477 (3394-3509)     <0.0001

Table 3: Predictive performance of hemoglobin, BMI, and total
lymphocyte count in predicting CD4 counts < 200 [mm.sup.-3].

Parameter                Cut-off   Sensitivity   Specificity    PPV

Total

Hb                        12.15       73.9%         56.8%      67.4%
BMI                       20.65       69.6%         80.1%      71.7%
Total lymphocyte count    1200        100%          100%       91.3%

HAART

Hb                        12.15        70%          63.8%      52.6%
BMI                       20.35        60%          77.8%       50%
Total lymphocyte count    1219         90%          100%       100%

HAART naive

Hb                        10.35       41.7%         90.4%      36.1%
BMI                        22         77.7%         78.8%      72.2%
Total lymphocyte count    1200        100%          100%       91.7%

Parameter                 NPV     AUC

Total

Hb                       21.2%   0.688
BMI                      51.4%   0.780
Total lymphocyte count   87.6%   1.000

HAART

Hb                       28.7    0.679
BMI                      56.4%   0.787
Total lymphocyte count   81.9%   1.000

HAART naive

Hb                       73.1    0.658
BMI                      80.8%   0.817
Total lymphocyte count   100%    1.000
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Kwantwi, Louis Boafo; Tunu, Bismark Kwame; Boateng, Daniel; Quansah, Dan Yedu
Publication:Journal of Biomarkers
Article Type:Report
Date:Jan 1, 2017
Words:3984
Previous Article:Cystatin-C as a Marker for Renal Impairment in Preeclampsia.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters